Literature DB >> 2663733

Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.

S M Singh1, S Sone, N Inamura, T Ogura.   

Abstract

The role of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in monocyte-mediated up-regulation of lymphokine-activated killer (LAK) cell induction by IL-2 was examined. Treatment of blood mononuclear cells (MNC) of healthy donors with GM-CSF for 4 days in the presence of IL-2 resulted in a significant increase in LAK activity against natural killer (NK)-resistant Daudi cells, as assessed by the 4 hr 51Cr-release assay. For determination of the role of GM-CSF in LAK induction, highly purified lymphocytes (greater than 99%) and monocytes (greater than 90%) were isolated from MNC by counter-flow centrifugal elutriation (CCE). Pre-treatment of monocytes for 4 days with GM-CSF before addition of lymphocytes plus IL-2 resulted in a significant dose-dependent increase in monocyte-mediated up-regulation of LAK induction, but in the absence of monocytes GM-CSF had no effect on LAK cell induction. Similarly, GM-CSF augmented the proliferative response of lymphocytes to IL-2 in the presence of monocytes as assessed by 3H-TdR uptake. Treatment with anti-GM-CSF antibody completely abolished up-regulation of LAK induction by GM-CSF-treated monocytes. When blood monocytes were separated into 5 fractions by CCE, GM-CSF-responding monocytes were found to be responsible for up-regulation of LAK induction. These results suggest that GM-CSF may be important in monocyte-mediated up-regulation of LAK cell induction in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663733     DOI: 10.1002/ijc.2910440130

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin.

Authors:  P J Kuppen; A M Eggermont; A Marinelli; E de Heer; C J van de Velde; G J Fleuren
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Soluble factors produced by macrophages/monocytes inhibit lymphokine-activated killer activity in rat splenocyte cultures.

Authors:  P J Kuppen; A M Eggermont; R B Quak; A Marinelli; C J van de Velde; G J Fleuren
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

3.  Augmentation by transferrin of IL-2-inducible killer activity and perforin production of human CD8+ T cells.

Authors:  A Nakamura; S Sone; R Nabioullin; K Sugihara; M Munekata; Y Nishioka; A Nii; T Ogura
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

4.  Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.

Authors:  K Yoneda; T Osaki; T Yamamoto; E Ueta
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

5.  Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.

Authors:  I Vollenweider; R Moser; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

6.  Characterization of tumor-necrosis-factor-gene-transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production.

Authors:  Y Itoh; Y Koshita; M Takahashi; N Watanabe; Y Kohgo; Y Niitsu
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

7.  Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.

Authors:  S Sone; E Kunishige; F Fawzy; H Yanagawa; A Nii; K Maeda; S Atagi; Y Heike; Y Nishioka; K Mizuno
Journal:  Jpn J Cancer Res       Date:  1991-06

8.  Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.

Authors:  K Takahashi; S Sone; S Saito; Y Kamamura; T Uyama; T Ogura; Y Monden
Journal:  Jpn J Cancer Res       Date:  1995-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.